New Therapies for Relapsed Myeloma

Dan Vogl, MD, MSCE, examines new therapies for relapsed myeloma by reviewing recent efficacy, safety and outcomes clinical trials. Agents reviewed include the proteasome inhibitors, the histone deacetylase inhibitors, the monoclonal antibodies and and ibrutinib, vemurafinib and other agents now entering the field.

 

 

Related Links


Published

May 18, 2016

Created by

Penn Physician VideoLink